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primary performance endpoint of 30-day mean aortic valve pressure
gradient was 11.55.2mmHg, as assessed by an independent core lab,
and was signiﬁcantly less than the performance goal of 18 mmHg
(P<0.001). The primary safety endpoint of 30-day all-cause mortality
was 4.2%. One-year follow-up data or death was available for 99.2%
(119/120) of patients (1 patient withdrew consent at day 13). At 1 year,
the rate of all-cause mortality was 10.9% (13/119), disabling stroke
was 3.4% (4/119), and disabling bleeding was 5.9% (7/119). There
were no repeat procedures for valve-related dysfunction, valve
migration, embolization, or TAV-in-TAV. A total of 31.9% (38/119)
patients had new permanent pacemaker implantation due to
new or worsened conduction disturbance. By independent core
lab adjudication, the 1-year mean aortic valve gradient was
12.65.7mmHg and mean aortic valve area was 1.70.5cm2. A total
of 88.6% patients had no or trivial paravalvular aortic regurgitation
at 1 year; no patient had moderate or severe paravalvular aortic
regurgitation.
CONCLUSIONS The Lotus Valve has demonstrated negligible para-
valvular regurgitation and low rates of death and stroke at 1 year.
The 2-year results of the REPRISE II CE-Mark trial will provide the
longest follow-up to date in the full cohort of 120 patients treated
with the Lotus Valve; results will be available for the ﬁrst time at
TCT 2015.
CATEGORIES STRUCTURAL: Valvular Disease: Aortic
KEYWORDS TAVI, TAVR, Transfemoral
TCT-110
Up to One Year Follow Up Results of Transcatheter Annuloplasty Ring
Multicentre Trial
Alec Vahanian,1 Karl-Heinz Kuck,2 Georg Nickenig,3 Ottavio Alﬁeri,4
Antonio Colombo,5 Stephan Baldus,6 Francesco Maisano7
1Bichat hospital 46 Rue Henri Huchard Paris 75018, Paris, France;
2Cardiology, Hamburg, Germany; 3Heart Center Bonn, University of
Bonn, Bonn, Germany; 4San Raffaele Hospital, Milan, Italy; 5EMO GVM
Centro Cuore Columbus/San Raffaele Hospital, Milan, Italy; 6University
Hospital of Cologne, Cologne, Germany; 7University Hospital Zürich,
Zürich, Switzerland
BACKGROUND The Cardioband system enables percutaneous im-
plantation of an adjustable “surgical-like” mitral annuloplasty ring
using a transseptal approach. The aim of this study was to evaluate
the feasibility, safety and up to 12 month outcome of Cardioband in
patients with secondary mitral regurgitation (MR) in a multicentre
study.
METHODS Between February 2013 and March 2015, 40 high-risk pa-
tients with signiﬁcant secondary MR were enrolled at 6 sites in
Europe. After a Heart Team evaluation all patients were screened by
echocardiography and cardiac CT to assess feasibility. Echocardio-
graphic data were analyzed by an independent core-lab. Mean age was
727 years; thirty patients were male (75%). Mean EuroScore II 9.0%
7.02% and median STS score 7.2 % (1.0%-34.0%). At baseline 93% of
patients were in NYHA class III-IV with mean left ventricular ejection
fraction of 33.310% (15%-57%). Device implantation was feasible in
all patients (100%).
RESULTS Acute procedural success (device successfully implanted
with acute reduction of MR <2þ) was achieved in 92% of the
patients (37/40). After cinching of the device, an average 20%
reduction in the septo-lateral diameter was observed (from 375 mm
to 295 mm; p<0.01). Thirty-day mortality was 5.0% (adjudicated as
unrelated to the device). At 6-month follow-up (N¼20) 80% of
patients were in NYHA class I-II with signiﬁcant improvement
in quality of life (MLWHFQ from 38 to 18; p<0.05) and 85% of
patients had MR2þ. At 12 month follow-up (N¼14), 70% of
patients were in NYHA class I-II with signiﬁcant improvement in
quality of life (MLWHFQ from 35 to 17; p<0.05 and signiﬁcant
improvement in 6MW from 288 m to 360 m; p<0.05); 93% of pa-
tients had MR<2þ).CONCLUSIONS Transseptal direct annuloplasty with an adjustable
“surgical-like” ring is feasible, with a comparable safety proﬁle similar
to other transcatheter mitral procedures. Effective reduction in MR
severity is observed in most patients related to a signiﬁcant septo-
lateral dimension reduction. MR reduction is stable and consistent up
to 12 months, with clinical beneﬁt.
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BACKGROUND Mitral regurgitation (MR) frequently accompanies
aortic stenosis (AS). Transcatheter aortic valve replacement (TAVR) is
an effective treatment for severe AS, but unlike surgical treatment,
cannot simultaneously address MR. The impact of concomitant MR on
TAVR outcomes requires better understanding, as does the impact of
TAVR on MR severity.
METHODS Patients who underwent TAVR between 1/2012 and 12/2013
in the STS-ACC TVT registry were analyzed for baseline and proce-
dural characteristics, in-hospital and 30 day clinical outcomes as well
as echo outcomes. Center for Medicare and Medicaid Services data
was obtained for longer-term outcomes.
RESULTS Of 11,221 patients who underwent TAVR, 3,497 (31%) had
baseline moderate (2þ) MR and 602 (5%) had severe (3 to 4þ) MR.
As compared to patients with minimal MR (0, trace, or 1þ),
patients with moderate or severe MR were older, more often female,
more likely NYHA class III-IV, had more atrial ﬁbrillation/ﬂutter, and
were more likely to have a preoperative pacemaker. Patients with
minimal MR had more diabetes, chronic severe lung disease, and
need for home O2. Echo/cath showed patients with moderate or
severe MR had lower ejection fractions, higher pulmonary artery
systolic and wedge pressures. STS predicted 30-day mortality in
minimal, moderate and severe MR patients were 8.1%, 9.6% and
10.7% respectively (p < 0.0001). MR improved at least 1 grade on
post-procedure (pre-discharge) echocardiogram in 79% of the severe
MR patients and 66% of the moderate MR patients. Unadjusted
death at 30 days in the minimal, moderate and severe MR patients
was 6.7%, 8.5% and 12.6%, respectively (p<0.0001). Unadjusted
death at 1 year was 22.3%, 27.1% and 28.2%, respectively (p<0.0001).
(Figure)
CONCLUSIONS Approximately one-third of patients presenting
for TAVR in US have moderate to severe preoperative MR.
B52 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5Following TAVR, the majority of these patients have at least one
grade improvement in the MR grade prior to discharge. Despite
this improvement, 30 day and 1 year mortality is signiﬁcantly
higher in those with moderate or severe MR than those with minimal
MR.None
Trace
Mild MR
(N[7122)Moderate MR
(N[3497)Severe MR
(N[602) P valueAge (y) 83 85 86 <0.001Female (%) 49 56 55 <0.001DM (%) 38 34 30 <0.001Prior MI (%) 25 27 25 0.33Prior CABG (%) 33 32 20 0.39Home O2 (%) 15 13 11 0.003Chronic lung
disease,
severe14 13 12 0.003Atrial ﬁbrillation
(%)37 47 53 <0.001AVG
mean mmHg44 43 43 0.006PASP mmHg 43 49 52 <0.001PCWP mmHg 18 20 22 <0.001LVEF (%) 59 55 53 <0.001Femoral access
(%)56 57 59 0.36Device success
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BACKGROUND Clopidogrel nonresponsiveness is a strong marker of
the risk of cardiac death and stent thrombosis after percutaneous
coronary intervention (PCI). It is unknown if clopidogrel non-
resposiveness is a nonmodiﬁable risk factor or if prasugrel with more
potent and predictable platelet inhibition as measured by ex vivo
techniques is associated with a positive effect on clinical outcome.
This study sought to investigate the efﬁcacy of prasugrel as compared
with clopidogrel in clopidogrel nonresponders.
METHODS REsponsiveness to CLOpidogrel and StEnt thrombosis
(RECLOSE)- 3 study screened clopidogrel nonresponders after a 600
mg loading dose of clopidogrel. Clopidogrel nonresponders switched
to prasugrel (10 mg/daily) the day of PCI, and ADP test (10 mmo/L of
ADP ) performed 6 days after PCI. The primary end point was 2-year
cardiac mortality. Patient outcome was compared with the RECLOSE-2
study.
RESULTS We screened 1,550 patients, and 302 were clopidogrel
nonresponders. The ADP test was 77.6  6.2%. After switching to
prasugrel the ADP test result was reduced to 47.1  16.8%. The 2-
year cardiac mortality rate was 4% in the RECLOSE-3 study and 9.7
% in nonresponders of the RECLOSE-2 study (p ¼ 0.007). The deﬁ-
nite/probable stent thrombosis rates were 0.7% and 4.4%, respec-
tively (p ¼ 0.004). At the ﬁnal multivariable analysis, prasugrel
treatment was related to the risk of 2-year cardiac death (HR 0.32,
p¼0.036) after adjusting for age, ACS and renal insufﬁciency.CONCLUSIONS Clopidogrel nonresponsiveness can be overcame by
prasugrel (10 mg/daily), and optimal platelet aggregation inhibition on
prasugrel treatment is associated with a low rate of long-term cardiac
mortality and stent thrombosis.
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